Atlas Capital Advisors LLC trimmed its position in shares of Centene Co. (NYSE:CNC – Free Report) by 19.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,455 shares of the company’s stock after selling 2,049 shares during the quarter. Atlas Capital Advisors LLC’s holdings in Centene were worth $561,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also made changes to their positions in the company. Rise Advisors LLC bought a new position in shares of Centene in the first quarter worth about $25,000. Riverview Trust Co increased its position in Centene by 154.6% during the second quarter. Riverview Trust Co now owns 527 shares of the company’s stock worth $35,000 after acquiring an additional 320 shares during the period. Neo Ivy Capital Management bought a new position in shares of Centene during the 4th quarter worth about $40,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Centene during the second quarter valued at about $36,000. Finally, Access Investment Management LLC acquired a new stake in Centene during the fourth quarter worth about $44,000. 93.63% of the stock is currently owned by institutional investors and hedge funds.
Centene Price Performance
Centene stock opened at $78.83 on Friday. The stock has a market cap of $42.07 billion, a price-to-earnings ratio of 15.67, a P/E/G ratio of 1.00 and a beta of 0.50. Centene Co. has a 12-month low of $60.83 and a 12-month high of $81.42. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.64. The business’s 50-day simple moving average is $72.11 and its 200 day simple moving average is $73.94.
Analyst Ratings Changes
A number of research firms have weighed in on CNC. Robert W. Baird started coverage on shares of Centene in a research note on Thursday, May 30th. They set a “neutral” rating and a $83.00 price target on the stock. Deutsche Bank Aktiengesellschaft upped their target price on shares of Centene from $82.00 to $87.00 and gave the company a “hold” rating in a research note on Friday, August 2nd. Baird R W raised Centene to a “hold” rating in a report on Thursday, May 30th. Barclays increased their target price on Centene from $90.00 to $98.00 and gave the stock an “overweight” rating in a report on Thursday, August 22nd. Finally, Oppenheimer cut their price objective on Centene from $110.00 to $95.00 and set an “outperform” rating for the company in a report on Monday, July 29th. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $84.77.
Check Out Our Latest Stock Analysis on Centene
Centene Profile
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.
Further Reading
- Five stocks we like better than Centene
- What is a Low P/E Ratio and What Does it Tell Investors?
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- What is the S&P/TSX Index?
- Why Dell Can Continue Winning in AI and Beyond
- What Are Trending Stocks? Trending Stocks Explained
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Want to see what other hedge funds are holding CNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centene Co. (NYSE:CNC – Free Report).
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.